EPISODE · Feb 27, 2025 · 8 MIN
Rethinking Premeds
from OncoPharm · host John Bossaer
Two recent publications suggest modifications to standard subcutaneous daratumumab pre-meds is safe...and saves time! Padmaraju et al experience from Chicago Med Center: https://doi.org/10.1093/oncolo/oyae158 Vazirnia et al experience from Mayo Clinic: https://doi.org/10.1200/OP.23.00470 We end summarizing some emerging evidence about the need, or lack thereof, for pre-paclitaxel H2RAs.
Embed this episode
Ready to play
Rethinking Premeds
0:00
8:35
1×
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.
Frequently Asked Questions
How long is this episode of OncoPharm?
This episode is 8 minutes long.
When was this OncoPharm episode published?
This episode was published on February 27, 2025.
Can I download this OncoPharm episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!